A. M. Brewster

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer

Ana M. González-Angulo, Argun Akçakanat, S. Liu et al. · Annals of Oncology · 2014 · 104 citations · Full text

Medicine, Oncology, Pharmacology +13

High-Density and Very-Low-Density Lipoprotein Have Opposing Roles in Regulating Tumor-Initiating Cells and Sensitivity to Radiation in Inflammatory Breast Cancer

Adam R. Wolfe, Rachel L. Atkinson, Jay P. Reddy et al. · International Journal of Radiation Oncology*Biology*Physics · 2015 · 68 citations

Medicine, Cancer Biology, Oncology +16

Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).

Ana M. González-Angulo, M. C. Green, James L. Murray et al. · Journal of Clinical Oncology · 2011 · 29 citations

Medicine, Oncology, Pharmacology +17

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer

Stacy L. Moulder, Gregory W. Gladish, Joe Ensor et al. · Cancer · 2011 · 27 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers

A. M. Brewster, C. Etzel, Ran Zhou et al. · Breast Cancer Research and Treatment · 2011 · 21 citations · Full text

Medicine, Oncology, Breast Oncology +15